Bayer's admission of 'mistake' underscores FDA's struggles

Share this article:
A Bayer admission that it "mistakingly" did not submit new risk information to the FDA on antibleeding drug Trasylol underscores the agency's struggle to get critical drug safety information out to the public. FDA had to replace a news release hours after it was issued to reflect new data.
Share this article:

Email Newsletters

More in News

Five things for pharma marketers to know: Friday, August 22

Five things for pharma marketers to know: Friday, ...

Two new indications give Eliquis more juice, a new rule is making hydrocodone harder to get and the ALS Ice Bucket Challenge highlights a controversial aspects of drug discovery and ...

Lilly takes on Amgen's Enbrel

Lilly takes on Amgen's Enbrel

Phase-III tests indicate Lilly's experimental treatment bests Amgen's for moderate-to-severe plaque psoriasis.

GSK Ellipta franchise expands

GSK Ellipta franchise expands

The FDA has approved Arnuity Ellipta for asthma.